• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Clinical Trials In Serbia If March 2009
 

Clinical Trials In Serbia If March 2009

on

  • 3,881 views

CT in SERBIA

CT in SERBIA

Statistics

Views

Total Views
3,881
Views on SlideShare
3,866
Embed Views
15

Actions

Likes
0
Downloads
33
Comments
0

3 Embeds 15

http://www.linkedin.com 8
http://www.slideshare.net 5
http://static.slideshare.net 2

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Clinical Trials In Serbia If March 2009 Clinical Trials In Serbia If March 2009 Presentation Transcript

    • Clinical Trials in Serbia Overview Dr Ivan Ferlez Senior Clinical Research Associate
    • OBJECTIVES
      • To present Serbia as a potential country for future CTs
      • To help understand opportunities and benefits of conducting CTs in Serbia
    • KEY ISSUES IN CT
      • Recruitment rate
      • Data quality
      • Experienced and well trained clinical trial staff
      • Local presence of internationally experienced CROs
      • Time to obtain import license
      • Time to obtain regulatory approvals
      • Suitable technical & medical infrastructure
      • Logistic support
    • “ There has never been a better time to conduct clinical research in Serbia , as the country has undeniably become one of the most popular destinations in this ever competitive field” Applied Clinical Trials, April 2006.
    • WHY SERBIA ?
      • Fast study start-up due to simplified, time-saving regulatory procedure
      • Fast patient recruitment due to the large population living in the major cities
      • E xpirienced physi c ians high ly motivat ed to participate in clinical trials
      • Lower costs of conducting clinical trials than in other European countries
    • PATIENT POPULATION
      • There are over 7.5 million inhabitants in Serbia , with 2 million living in Belgrade, the capital city
      • Large patient population is easily accessible-high recruitment rates can be achieved
      • Access to a large pool of untreated & treatment naïve patients
      • Patients are motivated to participate in clinical trials-compliance & follow-up during long-term studies are excellent
    • RECRUITMANT RATE
      • Fast patient recruitment
      • This is especially evident in oncology, cardiology, rare disease s and pediatric clinical trials ( increasingly difficult to conduct in Western countries because of considerable patient ’s reluctance )
      • Evidence Based Data: sample from Phase IIb CT
      • Serbia has the highest enrolling rate per CT
      • Successfully passed Sponsor internal audit in October 2008.
      Status on February 6, 2009 : 149 All countries 8 US 2 Croatia 2 Canada 1 Spain 10 Russia 1 Hungary 4 Lithuania 13 Israel 7 Italy 3 Slovenia 14 Poland 35 Serbia 49 Germany No. of patients Country
    • S ITE STAFF
      • Serbian providers offer high standards, competitive cost and superb recruitment rate
      • “ Study staff and monitors are, invariably physicians. The combination of highly educated professionals makes it possible to conduct very complex scientific protocols. This results in adherent to study schedules, significantly fewer protocol deviations and lower screen failure drop out rate.
      • ” Applied Clinical trials, 2004, Vol 13, No1
      • Educated and experienced physicians are highly motivated to participate in CTs
      • 400 physicians GCP-certified so far
    • DISCIPLINED APPROACH Source: MoH High ethics standards and educational mission in clinical trials Quantified quality control in place Good clinical practice (ICH) and standard operating Procedures .
    • ENGLISH LANGUAGE
      • Serbia has the highest percentage of English language speakers in southeastern and central Europe
      Investment Guide—Serbia , 2nd Edition, May 2005, Bank Austria Creditanstalt
    • NUMBER OF INITIATED CTs
      • During 2008. 130 CTs were initiated
      • Trial structure:
      • Phase I-5%
      • Phase II-25%
      • Phase III-50%
      • Phase IV-20%
      • CT are mainly conducted in Oncology, Rheumatology and Diabetes
      The medicine & Medical devices Agency of Serbia
    • REGULATORY REQUIREMENTS
      • EU directive is adopted
      • GCP Inspection (local, EMEA & FDA)
      • EC (for each site separately) prior to R A approval needed
        • EC approvals necessary for RA submission ; EC-approved centre can start the study upon RA approval ; Approval of additional centres is just administration.
      • R A:
        • meetings on a monthly bases (first Tuesday in a month) ;
        • approval time 4 weeks starting from submission ; Fee 1,400.00 EUR
      • EC:
        • organized by most of the big hospitals, accoding to ICH-GCP; No central EC.
        • meetings on a monthly bases or ad hoc .
        • approval time 4 – 6 weeks; Fee: up to 800.00 EUR
        • AVERAGE SET UP TIME IS 3 MONTHS
      The medicine & Medical devices Agency of Serbia
    • REGULATORY REQUIREMENTS EC and RA Approval P rocess
      • Documentation required :
        • Investigator’s brochure (English)
        • Signed protocol and amendments (English)
        • Protocol Synopsis (Serbian)
        • Informed consent form (Serbian)
        • CRFs
        • EC Approval s of participating centers
        • Written consent of the Head of institution
        • Investigational products documentation (GMP, CoA, Labelling – translated) RA
        • Investigator CVs
        • Local insurance policy
        • Other information for patients (i.e. patient card in Serbian)
        • Registration status (list of countries) – if registered
        • At least one EU country where the same CT is approved
        • Other documents, if needed
        • IMPD (RA)
        • Import license for study drug and lab kits issued with CT approval by RA
    • INFRASTRUCTION
        • 4 Clinical Centres
          • Largest comprehensive
          • Care Center
          • Tertiary care emphasis
          • High patient numbers across all localizations
          • 400 GCPcertified professionals
      Source: IORS Clinical Centre Nis , Niš Clinical Centre Serbia, Belgrade Clinical Centre Vojvodina, Novi Sad Clinical Centre Kragujevac , Kragujevac
    • Welcome to Serbia “ Over the past few years, Serbia has made a great step forward aiming to enrol grater number of clinical trials of high quality, high scientific and ethical standards for the ultimate benefit of the patients. … With above in mind, we welcome Sponsor and CRO companies to consider a more intensive cooperation with Serbia in the field of clinical trials.” DDS , Ivan Ferlez Senior Clinical Research Associate March , 2009.